105 related articles for article (PubMed ID: 19705967)
1. Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets.
Adams H; Campidelli C; Dirnhofer S; Pileri SA; Tzankov A
Expert Opin Ther Targets; 2009 Oct; 13(10):1137-45. PubMed ID: 19705967
[TBL] [Abstract][Full Text] [Related]
2. AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features.
Rodig SJ; Ouyang J; Juszczynski P; Currie T; Law K; Neuberg DS; Rabinovich GA; Shipp MA; Kutok JL
Clin Cancer Res; 2008 Jun; 14(11):3338-44. PubMed ID: 18519761
[TBL] [Abstract][Full Text] [Related]
3. BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's lymphoma from primary mediastinal large B-cell lymphoma.
Hoeller S; Zihler D; Zlobec I; Obermann EC; Pileri SA; Dirnhofer S; Tzankov A
Histopathology; 2010 Jan; 56(2):217-28. PubMed ID: 20102401
[TBL] [Abstract][Full Text] [Related]
4. Classical Hodgkin's lymphoma arising in different host's conditions: pathobiology parameters, therapeutic options, and outcome.
Carbone A; Spina M; Gloghini A; Tirelli U
Am J Hematol; 2011 Feb; 86(2):170-9. PubMed ID: 21264899
[TBL] [Abstract][Full Text] [Related]
5. Detection of immunoglobulin heavy chain gene rearrangements in classic hodgkin lymphoma using commercially available BIOMED-2 primers.
Chute DJ; Cousar JB; Mahadevan MS; Siegrist KA; Silverman LM; Stoler MH
Diagn Mol Pathol; 2008 Jun; 17(2):65-72. PubMed ID: 18382369
[TBL] [Abstract][Full Text] [Related]
6. Classical Hodgkin lymphoma concurrently evolving in a patient with marginal zone B-cell lymphoma of the spleen.
Harada S; Kalla H; Balasubramanian M; Brodsky I; Gladstone D; Hou JS
Ann Diagn Pathol; 2008 Jun; 12(3):212-6. PubMed ID: 18486899
[TBL] [Abstract][Full Text] [Related]
7. Distinguishing Classical Hodgkin Lymphoma, Gray Zone Lymphoma, and Large B-cell Lymphoma: A Proposed Scoring System.
O'Malley DP; Fedoriw Y; Weiss LM
Appl Immunohistochem Mol Morphol; 2016 Sep; 24(8):535-40. PubMed ID: 26447896
[TBL] [Abstract][Full Text] [Related]
8. U-HO1, a new cell line derived from a primary refractory classical Hodgkin lymphoma.
Mader A; Bruderlein S; Wegener S; Melzner I; Popov S; Muller-Hermelink HK; Barth TF; Viardot A; Moller P
Cytogenet Genome Res; 2007; 119(3-4):204-10. PubMed ID: 18253030
[TBL] [Abstract][Full Text] [Related]
9. BCL2 and BCL3 are recurrent translocation partners of the IGH locus.
Szymanowska N; Klapper W; Gesk S; Küppers R; Martín-Subero JI; Siebert R
Cancer Genet Cytogenet; 2008 Oct; 186(2):110-4. PubMed ID: 18940474
[TBL] [Abstract][Full Text] [Related]
10. [Post-transplantation malignant tumors and the challenges of immunosuppressive therapy in transplanted patients developing lymphoma. Mycophenolic acid as a possibility].
Végso G
Magy Onkol; 2009 Jun; 53(2):149-56. PubMed ID: 19581181
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometry can diagnose classical hodgkin lymphoma in lymph nodes with high sensitivity and specificity.
Fromm JR; Thomas A; Wood BL
Am J Clin Pathol; 2009 Mar; 131(3):322-32. PubMed ID: 19228638
[TBL] [Abstract][Full Text] [Related]
12. Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival.
Muenst S; Hoeller S; Dirnhofer S; Tzankov A
Hum Pathol; 2009 Dec; 40(12):1715-22. PubMed ID: 19695683
[TBL] [Abstract][Full Text] [Related]
13. Calcineurin inhibitors and post-transplant hyperlipidaemias.
Moore R; Hernandez D; Valantine H
Drug Saf; 2001; 24(10):755-66. PubMed ID: 11676303
[TBL] [Abstract][Full Text] [Related]
14. Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas.
Miles RR; Mankey CC; Seiler CE; Smith LB; Teruya-Feldstein J; Hsi ED; Elenitoba-Johnson KS; Lim MS
Hum Pathol; 2009 Dec; 40(12):1731-7. PubMed ID: 19716163
[TBL] [Abstract][Full Text] [Related]
15. Therapy-related classical Hodgkin lymphoma after a primary haematological malignancy: a report on 13 cases.
Cheminant M; Galicier L; Brière J; Boutboul D; Micléa JM; Venon MD; Robin M; Thieblemont C; Brice P
Br J Haematol; 2012 Sep; 158(5):644-8. PubMed ID: 22734472
[TBL] [Abstract][Full Text] [Related]
16. Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic implications.
Ong KW; Teo M; Lee V; Ong D; Lee A; Tan CS; Vathsala A; Toh HC
Clin Cancer Res; 2009 Sep; 15(17):5350-8. PubMed ID: 19706821
[TBL] [Abstract][Full Text] [Related]
17. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
[TBL] [Abstract][Full Text] [Related]
18. Pancreas transplant outcomes for United States (US) cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR).
Gruessner AC; Sutherland DE
Clin Transpl; 2008; ():45-56. PubMed ID: 19708445
[TBL] [Abstract][Full Text] [Related]
19. Extramedullary plasmacytoma-like posttransplantation lymphoproliferative disorders: clinical and pathologic features.
Richendollar BG; Hsi ED; Cook JR
Am J Clin Pathol; 2009 Oct; 132(4):581-8. PubMed ID: 19762536
[TBL] [Abstract][Full Text] [Related]
20. Genetic associations in classical hodgkin lymphoma: a systematic review and insights into susceptibility mechanisms.
Kushekhar K; van den Berg A; Nolte I; Hepkema B; Visser L; Diepstra A
Cancer Epidemiol Biomarkers Prev; 2014 Dec; 23(12):2737-47. PubMed ID: 25205514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
